Literature DB >> 33468199

The lymph node ratio predicts cancer-specific survival of node-positive non-small cell lung cancer patients: a population-based SEER analysis.

Liu Kai1, Chen Zhoumiao1, Xu Shaohua1, Chen Zhao1, Li Zhijun1, He Zhengfu1, Cai Xiujun2.   

Abstract

BACKGROUND: Lymph node ratio (LNR) has been suggested to be an effective prognostic tool for stratifying non-small cell lung cancer (NSCLC) cases. In this study, we sought to determine cancer-specific survival (CCS) of NSCLC cases from the SEER registry and used the X-tile method to optimize CCS-based LNR cut-off points for prognostic stratification of node-positive NSCLC.
METHODS: CSS and other clinicopathologic variables were retrieved from the SEER registry. Kaplan-Meier methods were used to calculate CSS. The optimal cut-off points for LNR classification were determined by the X-tile approach. Multivariate Cox regression analysis was performed to identify independent risks of CSS.
RESULTS: Totally 11,341 lung cancer patients were included. Their median CSS was 22 months (range 0,143). The median LNR was 0.22 (Q1,Q3: 0.11, 0.50). X-tile analysis showed that the optimal LNR cut-off points were 0.28 and 0.81, dividing the cohort into low (LNR1 ≤ 0.28; n = 6580, 58%), middle (0.28 < LNR2 < 0.81; n = 3025, 26.7%), and high (LNR3 > 0.81; n = 1736, 15.3%) subsets. Kaplan-Meier analysis showed that patients with a low LNR had a significantly higher CCS versus patients with middle or high LNR (P < 0.001). Multivariate competing risks regression analysis revealed that LNR was an independent and significant adverse predictor of CSS (LNR2 vs. LNR1: SHR: 1.56, 95%CI: 1.47,1.67, P < 0.001; LNR3 vs. LNR1: SHR: 2.54, 95%CI: 2.30,2.80, P < 0.001).
CONCLUSIONS: LNR is an independent prognostic factor of node-positive NSCLC and its optimal cut-off values established using the robust x-tile method effectively define subpopulations of node-positive NSCLC cases, which is important in guiding selection of treatment strategies clinically.

Entities:  

Keywords:  Lymph node ratio; Node-positive; Non-small cell lung cancer; Survival

Mesh:

Year:  2021        PMID: 33468199      PMCID: PMC7814600          DOI: 10.1186/s13019-020-01390-x

Source DB:  PubMed          Journal:  J Cardiothorac Surg        ISSN: 1749-8090            Impact factor:   1.637


  25 in total

1.  Lymph node ratio predicts recurrence and survival after R0 resection for non-small cell lung cancer.

Authors:  Matthew D Taylor; Damien J LaPar; Christopher J Thomas; Matthew Persinger; Edward B Stelow; Benjamin D Kozower; Christine L Lau; David R Jones
Journal:  Ann Thorac Surg       Date:  2013-08-30       Impact factor: 4.330

2.  Proposal of new nodal classifications for non-small-cell lung cancer based on the number and ratio of metastatic lymph nodes.

Authors:  Haruhisa Matsuguma; Izumi Oki; Rie Nakahara; Norihisa Ohata; Seiji Igarashi; Kiyoshi Mori; Shunsuke Endo; Kohei Yokoi
Journal:  Eur J Cardiothorac Surg       Date:  2012-01       Impact factor: 4.191

3.  Lymph-node ratio predicts survival among the different stages of non-small-cell lung cancer: a multicentre analysis†.

Authors:  Marco Chiappetta; Giovanni Leuzzi; Isabella Sperduti; Emilio Bria; Felice Mucilli; Filippo Lococo; Lorenzo Spaggiari; Giovanni Battista Ratto; Pier Luigi Filosso; Francesco Facciolo
Journal:  Eur J Cardiothorac Surg       Date:  2019-03-01       Impact factor: 4.191

4.  Demonstration of the skip metastasis pathway for N2 non-small cell lung cancer.

Authors:  Hiromitsu Takizawa; Shoji Sakiyama; Mitsuhiro Tsuboi; Akira Tangoku
Journal:  J Thorac Cardiovasc Surg       Date:  2014-01-15       Impact factor: 5.209

5.  Lymph node ratio as a prognostic factor in elderly patients with pathological N1 non-small cell lung cancer.

Authors:  Juan P Wisnivesky; Jacqueline Arciniega; Grace Mhango; John Mandeli; Ethan A Halm
Journal:  Thorax       Date:  2010-12-02       Impact factor: 9.139

6.  Prognostic significance of the extent of lymph node involvement in stage II-N1 non-small cell lung cancer.

Authors:  Zi-Ming Li; Zheng-Ping Ding; Qing-Quan Luo; Chun-Xiao Wu; Mei-Lin Liao; Ying Zhen; Zhi-Wei Chen; Shun Lu
Journal:  Chest       Date:  2013-10       Impact factor: 9.410

7.  Skip mediastinal lymph node metastasis and lung cancer: a particular N2 subgroup with a better prognosis.

Authors:  Marc Riquet; Jalal Assouad; Patrick Bagan; Christophe Foucault; Françoise Le Pimpec Barthes; Antoine Dujon; Claire Danel
Journal:  Ann Thorac Surg       Date:  2005-01       Impact factor: 4.330

8.  [Determination of sentinel lymph node by Tc(99m) in small-cell lung cancer].

Authors:  Arife Zeybek; Alpay Sarper; Abdullah Erdoğan; Levent Dertsiz; Abid Demircan
Journal:  Tuberk Toraks       Date:  2014

9.  The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer.

Authors:  Valerie W Rusch; John Crowley; Dorothy J Giroux; Peter Goldstraw; Jung-Gi Im; Masahiro Tsuboi; Ryosuke Tsuchiya; Johan Vansteenkiste
Journal:  J Thorac Oncol       Date:  2007-07       Impact factor: 15.609

10.  Lymph node ratio as a prognostic factor in patients with pathological N2 non-small cell lung cancer.

Authors:  Masaya Tamura; Isao Matsumoto; Daisuke Saito; Shuhei Yoshida; Munehisa Takata; Hirofumi Takemura
Journal:  World J Surg Oncol       Date:  2016-11-25       Impact factor: 2.754

View more
  2 in total

1.  Clinical assessment of T2 papillary thyroid carcinoma: a retrospective study conducted at a single tertiary institution.

Authors:  Hyesung Kim; Kwangsoon Kim; Ja Seong Bae; Jeong Soo Kim
Journal:  Sci Rep       Date:  2022-08-08       Impact factor: 4.996

2.  Lymph node ratio predicts overall survival in patients with stage II non-small cell lung cancer: a population-based SEER analysis.

Authors:  Nan Feng; Bo Wu; Xiang Zhang; Jianhui Chen; Zhongtian Xiang; Yiping Wei; Wenxiong Zhang
Journal:  Discov Oncol       Date:  2022-08-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.